145,476 Shares in AngioDynamics, Inc. $ANGO Purchased by White Pine Capital LLC

White Pine Capital LLC purchased a new position in AngioDynamics, Inc. (NASDAQ:ANGO – Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 145,476 shares of the medical instruments supplier’s stock, valued at approximately $2,237,000. White Pine Capital LLC owned 0.35% of AngioDynamics at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Canada Pension Plan Investment Board bought a new position in shares of AngioDynamics in the second quarter worth approximately $428,000. Bank of America Corp DE purchased a new stake in shares of AngioDynamics in the second quarter worth $4,490,000. Western Standard LLC purchased a new stake in shares of AngioDynamics in the second quarter worth $5,037,000. Paradigm Capital Management Inc. NY bought a new stake in shares of AngioDynamics during the 2nd quarter valued at $8,732,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of AngioDynamics during the 2nd quarter valued at $1,619,000. 89.43% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ANGO. Wall Street Zen cut shares of AngioDynamics from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Zacks Research upgraded AngioDynamics from a “strong sell” rating to a “hold” rating in a research note on Monday, October 5th. Canaccord Genuity Group reissued a “buy” rating and set a $20.00 price target on shares of AngioDynamics in a report on Friday, October 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a report on Thursday, October 15th. Finally, HC Wainwright lowered their price objective on AngioDynamics from $19.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, October 13th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $19.00.

Check Out Our Latest Research Report on ANGO

AngioDynamics Stock Performance

Shares of NASDAQ:ANGO opened at $11.87 on Monday. The firm has a fifty day moving average price of $13.42 and a 200 day moving average price of $12.54. AngioDynamics, Inc. has a fifty-two week low of $9.39 and a fifty-two week high of $16.29. The firm has a market cap of $499.18 million, a price-to-earnings ratio of -15.22 and a beta of 0.30.

AngioDynamics (NASDAQ:ANGO – Get Free Report) last posted its earnings results on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.07. The company had revenue of $80.92 million during the quarter, compared to analysts’ expectations of $80.51 million. AngioDynamics had a negative net margin of 10.12% and a negative return on equity of 4.49%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, research analysts predict that AngioDynamics, Inc. will post -0.27 earnings per share for the current year.

Insider Buying and Selling at AngioDynamics

In other news, CFO Stephen Trowbridge sold 23,615 shares of AngioDynamics stock in a transaction dated Thursday, October 29th. The stock was sold at an average price of $12.27, for a total value of $289,756.05. Following the sale, the chief financial officer directly owned 280,461 shares of the company’s stock, valued at approximately $3,441,256.47. The trade was a 7.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 6.00% of the stock is currently owned by insiders.

About AngioDynamics

(Free Report)

AngioDynamics, Inc. develops, manufactures and markets medical devices used in minimally invasive procedures. Its products are designed for clinicians in areas including vascular access, peripheral vascular disease and oncology. The company’s offerings include vascular access devices such as ports and catheters, as well as technologies used in vascular intervention and cancer treatment. These include the Auryon atherectomy system, which is used to treat certain peripheral arterial conditions, and the NanoKnife System, which uses irreversible electroporation in tumor ablation procedures.

See Also

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.